

Serial No. 10/517,010


Remarks

Applicants have become aware of transcription errors that occurred during construction of the table identified as “Table I (Continued) Mineralocorticoid and Glucocorticoid Receptor Binding Values” which appears at pages 125 through 144 of the specification. With the present amendment, Applicants wish to remove from the table, the rows associated with these transcription errors. As the present amendment only relates to the deletion of rows from the table, it is Applicants' position that this amendment constitutes no added matter.

Applicants are proposing this amendment in accordance with 37 C.F.R. 1.121(b)(1) which sets forth the manner for replacing a paragraph in the specification. While Applicants recognize that the table to be amended is not a typical paragraph, the provisions of 37 C.F.R. 1.121(b)(1) were the most amenable to the amendment proposed herein.

Applicant kindly requests entry of the proposed amendment and consideration of the remarks herein.

Respectfully submitted,



Alexander Wilson
Attorney for Applicants
Registration No. 45,782
Phone: 317-277-0190

Eli Lilly and Company
Patent Division/AW
P.O. Box 6288
Indianapolis, Indiana 46206-6288

05 April 2006